Biologic effects of fenbendazole in rats and mice: A review

Journal of the American Association for Laboratory Animal Science

Volumn 46, Issue 6, 2007, Pages 8-15

  Villar, David ^a   Cray, Carolyn ^a   Zaias, Julia ^a   Altman, Norman H ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNEXIN 32; CYTOCHROME P450; FENBENDAZOLE; GLUTATHIONE TRANSFERASE; ANTINEMATODAL AGENT; CARCINOGEN;

B LYMPHOCYTE; BONE MARROW SUPPRESSION; CARCINOGENESIS; CELL PROLIFERATION; DNA DAMAGE; DRUG EFFECT; DRUG SAFETY; IMMUNE RESPONSE; IN VIVO STUDY; INTOXICATION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER HYPERPLASIA; LIVER TOXICITY; LIVER TUMOR; MAXIMUM TOLERATED DOSE; MITOGENESIS; NONHUMAN; PROTEIN FOLDING; REPRODUCTION; REVIEW; T LYMPHOCYTE; TERATOGENICITY; WORLD HEALTH ORGANIZATION; ANIMAL; BONE MARROW; ENTEROBIASIS; EXPERIMENTAL ANIMAL; IMMUNE SYSTEM; MOUSE; RAT;

ANIMALIA; ENTEROBIUS VERMICULARIS; MUS; RATTUS; RODENTIA;

ANIMALS; ANIMALS, LABORATORY; ANTINEMATODAL AGENTS; BONE MARROW; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; ENTEROBIASIS; FENBENDAZOLE; IMMUNE SYSTEM; MICE; RATS;

EID: 38449084702     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Agersborg SS, Garza KM, Tung KSK. 2001. Intestinal parasitism terminates self tolerance and enhances neonatal induction of autoimmune disease and memory. Eur J Immunol 31:851-859.
2. Baliharova V, Skalova L, Mass RFM, De Vrieze G, Bull S, Fink-Gremmels J. 2003. The effects of benzimidazole anthelmintics on P4501A in rat hepatocytes and HepG2 cells. Res Vet Med 75:61-69.
3. Baliharova V, Velik J, Šavlik M, Szotakova B, LAmka J, Tahotna L, Skalova L. 2004. The effects of fenbendazole, flubendazole and mebendazole on activities of hepatic cytochromes P450 in pig. J Vet Pharmacol Therap 27:85-90.
4. Barlow SC, Brown MM, Price HV. 2005. Eradication of Syphacia muris from food-restricted rats without environmental decontamination. Contemp Top Lab Anim Sci 44:23-25.
5. Barron S, Baseheart BJ, Segar TM, Deveraux T, Willford JA. 2000. The behavioral teratogenic potential of fenbendazole: a medication for pinworm infestation. Neurotoxicol Teratol 22:871-877.
6. Benchaoui HA, and McKellar QA. 1996. Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. J Pharm Pharmacol 48:753-759.
7. Bugarski D, Jovcic G, Katic-Radivojevic S, Petakov M, Krstic A, Stojanovic N, Milenkovic P. 2006. Hematopoietic changes and altered reactivity of IL-17 in Syphacia obvelata-infected mice. Parasitol Int 55:91-97.
8. Cabaj W, Stankiewicz M, Jonas WE, Moore LG. 1994. Fenbendazole and its effect on the immune system of the sheep. N Z Vet J 42:216-220.
9. Campbell WC. 1990. Benzimidazoles: veterinary uses. Parasitol Today 6:130-133.
10. Chen J. 2005. Animal models for acquired bone marrow failure syndromes. Clin Med Res 3:102-108.
11. Coghlan LG, Lee DR, Psencik B, Weiss D. 1993. Practical and effective eradication of pinworms (Syphacia muris) in rats by use of fenbendazole. Lab Anim Sci 43:481-486.
12. Dalvi RR, Gawai KR, Dalvi PS. 1991. Lack of in vivo and in vitro effects of fenbendazole on phase I and phase II biotransformation enzymes in rats, mice and chickens. Vet Hum Toxicol 33:548-551.
13. Dawson PJ, Gutterdge WE, Gull K. 1984. A comparison of the interaction of anthelmintic benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode Ascadidia Galli. Biochem Pharmacol 33:1069-1074.
14. Dey A, Jones JE, Nebert DW. 1999. Tissue and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization. Biochem Pharmacol 58:525-537.
15. Dvoroznakova E, Boroskova Z, Dubinsky P, Velebny S, Tomasovicova O, Machnicka B. 1998. Changes in cellular immunity of mice treated for larval toxocarosis with fenbendazole. Helminthologia 35:189-195.
16. Franke DDH, Shirwan H. 2006. Prophylactic fenbendazole therapy does not affect the incidence and onset of type 1 diabetes in non-obese diabetic mice. Int Immunol 18:453-458.
17. Gary AT, Kerl ME, Wiedmeyer CE, Turnquist SE, Cohn LA. 2004. Bone marrow hypoplasia associated with fenbendazole administration in a dog. J Am Anim Hosp Assoc 40:224-229.
18. Gleizes-Escala C, Lesca P, Larrieu G, Dupuy J, Pineau T, Galtier P. 1996. Effect of exposure of rabbit hepatocytes to sulfur-containing anthelmintics (oxfenbendazole and fenbendazole) on cytochrome P4501A1 expression. Toxicol In Vitro 10:129-139.
19. Goldenthal EI. 1980. Three-generation reproduction study in rats. Mattawan (MI): International Research and Development Corporation.
20. Godenthal EI. 1980. 24-month oral carcinogenicity study in mice. Mattawan (MI): International Research and Development Corporation.
21. Godenthal EI. 1980. Lifetime oral toxicity study in rats. Mattawan (MI): International Research and Development Corporation.
22. Gozalo AS, Schwiebert RS, Lawson GW. 2006. Mortality associated with fenbendazole administration in pigeons (Columba livia). J Am Assoc Lab Anim Sci 45:63-66.
23. Hill WA, Randolph MM, Lokey SJ, Hayes E, Boyd KL, Mandrell TD. 2006. Efficacy and safety of topical selamectin to eradicate pinworm (Syphacia spp. ) infections in rats (Rattus norvegicus) and mice (Mus musculus). J Am Assoc Lab Anim Sci 45:23-26.
24. Hiroi T, Miyazaki Y, Kobayashi Y, Imaoka S, Funae Y. 1995. Induction of hepatic P450s in rat by essential wood and leaf oils. Xenobiotica 25:457-467.
25. Holden HE, Crider PA, Wahrenburg MG. 1980. Mitotic arrest by benzimidazole analogs in human lymphocytes cultures. Environ Mutagen 2:67-73.
26. Howard LL, Papendick R, Stalis IH, Allen JL, Sutheland-Smith M, Zuba JR, Ward DL, Rideout BA. 2002. Fenbendazole and albendazole toxicity in pigeons and doves. J Avian Med Surg 16:203-210.
27. Huerkamp MJ, Benjamin KA, Webb SK, Pullium JK. 2004. Long-term results of dietary fenbendazole to eradicate Syphacia muris from rat colonies. Contemp Top Lab Anim Sci 43:35-36.
28. Huerkamp MJ, Kimberley AB, Zitzow LA, Pullium JK, Lloyd JA, Thompson WD, Webb SK, Lehner NDM. 2000. Fenbendazole treatment without environmental decontamination eradicates Syphacia muris from all rats in a large, complex research institution. Contemp Top Lab Anim Sci 39:9-12.
29. Hunter RL, Dong-Young C, Kincer JF, Cass WA, Bing G, Gash DM. 2007. Fenbendazole treatment may influence lipopolysaccharide effects in rat brain. Comp Med 57:487-492.
30. Jackson TA, Hall JE, Boivin GP. 1998. Ivermectin toxicity in multiple mouse lines. Lab Anim Pract 31:37-41.
31. Jacoby RO, Lindsey JR. 1997. Health care for research animals is essential and affordable. FASEB J 11:609-614.
32. Johnston NA, Bieszcak JR, Verhulst S, Disney KE, Montgomery KE, Toth LA. 2006. Fenbendazole treatment and litter size in rats. J Am Assoc Lab Anim Sci 45:35-39.
33. Katiyar SK, Gordon VR, McLaughlin GL, Edlind TD. 1994. Antiprotozoal activities of benzimidazoles and correlations with β-tubulin sequence. Antimicrob Agents Chemother 38:2086-2090.
34. Keen RG, Macinnis MLM, Guilhardi P, Chamberland KA, Church RM. 2005. The lack of behavioral effects of fenbendazole: a medication for pinworms infection. Contemp Top Lab Anim Sci 44:17-23.
35. Krutovskikh VA, Mesnil M, Mazzoleni G, Yamasaki H. 1995. Inhibition of rat liver gap junction intercellular communication by tumor-promoting agents in vivo. Lab Invest 72:571-577.
36. Kuribayashi M, Asamoto M, Suzuki S, Hokaiwado N, Ogawa K, and Shirai T. 2006. Lack of modification of 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline (MeIQx) rat hepatocarcinogenesis by caffeine, a CYP1A2 inducer, points to complex counteracting influences. Cancer Lett 232:289-299.
37. Lake BG, Renwick AB, Cunninghame ME, Price RJ, Surry D, Evans DC. 1998. Comparison of the effects of some CYP3A and other enzyme inducers on replicative DNA synthesis and cytochrome P450 isoforms in rat liver. Toxicology 131:9-20.
38. Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM. 2005. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res 65:3726-3734.
39. Löfgren S, Habgjork AL, Ekman S, Fransson-steen R, Terelius Y. 2004. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica 34:811-834.
40. Mandal PK. 2005. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J Comp Physiol B 175:221-230.
41. McNair DM, Timmons EH. 1977. Effects of Aspiculuris tetraptera and Syphacia obvelata on exploratory behavior of an inbred mouse strain. Lab Anim Sci 27:38-42.
42. Michels C, Goyal P, Nieuwenhuizen N, Brombacher F. 2006. Infection with Syphacia obvelata (pinworm) induces protective Th2 immune responses and influences ovoalbumin-induced allergic reactions. Infect Immun 74:5926-5932.
43. Mitsumori K, Onodera H, Shoda T, Uneyama C, Imazawa T, Takegawa K, Yasuhara K, Watanabe T, and Takahashi M. 1997. Liver tumor-promoting effects of oxfenbendazole in rats. Food Chem Toxicol 35:799-806.
44. Mohn G, Philipp EM. 1981. Effects of Syphacia muris and the anthelmintic fenbendazole on the microsomal monooxygenase system in mouse liver. Lab Anim 15:89-95.
45. Moon YJ, Wang X, Morris ME. 2006. Dietary flavonoids: effects of xenobiotic and carcinogen metabolism. Toxicol In Vitro 20:187-210.
46. Murray M, Hudson AM, Yassa V. 1992. Hepatic microsomal metabolism of the anthelmintic benzimidazole fenbendazole: enhanced inhibition of cytochrome P450 reactions by oxidized metabolites of the drug. Chem Res Toxicol 5:60-66.
47. Nakamato T, Oda Y, Imaoka S, Funae Y, Fujimori M. 1997. Effect of phenobarbital on the pharmacokinetics of lidocaine monoethylglycinexylidide and 3-hydroxylidocaine in the rat: correlation with P450 isoform levels. Drug Metab Disp 25:296-300.
48. Neiffer DL, Lydick D, Burks K, Doherty D. 2005. Hematologic and plasma biochemical changes associated with fenbendazole administration in Hermann's tortoises (Testudo hermanni). J Zoo Wildlife Med 36:661-672.
49. Parish SJ, McFarlane RG, Familton AS, Abell TJ. 1996. The effect of fenbendazole on the immune system of lambs. Proc New Zealand Soc Anim Prod 56:80-83.
50. Philip M, Rowley DA, Schreiber H. 2004. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14:433-439.
51. Pitot HC, Dragan Y, Sargent L, Xu YH. 1991. Biochemical markers associated with the stages of promotion and progression during hepatocarcinogenesis in the rat. Environ Health Perspect 93:181-189.
52. Plumb DC. 1999. Veterinary drug handbook, 3rd ed. Ames (IA): Iowa State University Press.
53. Pritchett KR, Johnston NA. 2002. A review of treatments for the eradication of pinworm infections from laboratory rodent colonies. Contemp Top Lab Anim Sci 41: 36-46.
54. Redbook 2000 [Internet]. Toxicological principles for the safety assessment of food ingredients: 2007 update [cited 26 Sep 2007]. Available at http://www.cfsan.fda.gov/~redbook/red-ivc6.html.
55. Reiss CS, Herrman JM, Hopkins RE. 1987. Effect of anthelminthic treatment on the immune response of mice. Lab Anim Sci 37:773-775.
56. Sajid MS, Muhammad ZIG, Iqbal MU. 2006. Immunomodulatory effect of various anti-parasitics: a review. Parasitology 132:301-313.
57. Samson-Himmelstjerna G, Witzendorff C, Sievers G, Schnieder T. 2002. Comparative use of faecal egg count reduction test, egg hatch assay, and beta-tubulin codon 200 genotyping in small strongyles (cyathostominae) before and after benzimidazole treatment. Vet Parasitol 108:227-235.
58. Sato K. 1988. Glutathione-S-transferases and hepatocarcinogenesis. Jpn J Cancer Res 79:556-572.
59. Šavlík M, Fimanova K, Szotakova B, Lamka J, Skalova L. 2006. Modulation of porcine biotransformation enzymes by anthelmintic therapy with fenbendazole and flubendazole. Res Vet Med 80:267-274.
60. Scholz H and Schultes E. 1973a. Report on an acute oral safety evaluation of the anthelmintic HOE 881 in mice. Frankfurt am Main (Germany): Hoechst-Roussel.
61. Scholz H and Schultes E. 1973b. Report on an acute oral safety evaluation of the anthelmintic HOE 881 in rats. Frankfurt am Main (Germany): Hoechst-Roussel.
62. Shimada T, Oda Y, Gillan EM, Guengerich P, Inoue K. 2001. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P4501A1 and P4501B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab Disp 29:1176-1182.
63. Shirai T. 1997. A medium-term rat liver bioassay as a rapid in vivo test for carcinogenic potential: a historical review of model development and summary of results from 291 tests. Toxicol Pathol 25:453-460.
64. Shi-Xin X, Ding Z, Yu-Mei S, Shu-Huai W, Li-Qing S. 1992. Subchronic toxicity studies of fenbendazole in rats. Vet Hum Toxicol 34:411-413.
65. Shoda T, Onodera H, Takeda M, Uneyama C, Imazawa T, Takegawa K, Yasuhara K, Watanabe T, Hirose M, Mitsumori K. 1999. Tumor promoting effects of fenbendazole in rats. Toxicol Pathol 27:553-562.
66. Short CR, Barker SA, Hsieh LC, Ou SP, McDowell T. 1988. Disposition of fenbendazole in the rabbit. Res Vet Sci 44:215-219.
67. Short CR, Flory W, Hsieh LC, Barker SA. 1988. The oxidative metabolism of fenbendazole: a comparative study. J Vet Pharmacol Therap 11:50-55.
68. Silveira AC, Gilioli R, Oliveira ES, Bassani RA. 2002. Subsensitivity to beta-adrenergic stimulation in atria from rats infested with Syphacia sp. Lab Anim 37:63-67.
69. Stankiewicz M, Cabaj W, Jonas WE, Moore LG, Chie WNG. 1994. Oxfenbendazole treatment of non-parasitized lambs and its effect on the immune system. Vet Res Commun 18:7-18.
70. Suzuki S, Takahashi S, Asamoto K, Inaguma S, Ogiso T, Hirose M, Shirai T. 2002. Lack of modification of 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline (MeIQx)-induced hepatocarcinogenesis in rats by fenbendazole - a CYP1A2 inducer. Cancer Lett 185:39-45.
71. Taffs LF. 1976. Pinworm infections in laboratory rodents: a review. Lab Anim 10: 1-13.
72. Toth LA, Oberbeck C, Straign CM, Frazier S, Rehg JE. 2000. Toxicity evaluation of phophylactic treatments for mites and pinworms in mice. Contemp Topics Lab Anim Sci 39:18-21.
73. Trosko JE, Ruch RJ. 2002. Gap junctions as targets for cancer chemoprevention and chemotherapy. Curr Drug Targets 3:1-17
74. Turesky RJ, Constable A, Richoz J, Varga N, Markovic J, Martin MV, Guengerich FP. 1998. Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P4501A2. Chem Res Toxicol 11:925-936.
75. Wagner M. 1988. The effect of infection with the pinworm (Syphacia muris) on rat growth. Lab Anim Sci 38:476-478.
76. Weber MA, Miller MA, Neiffer DL, Terrell SP. 2006. Presumptive fenbendazole toxicosis in North Amercian porcupines. J Am Vet Med Assoc 228:1240-1242.
77. World Health Organization [Internet]. WHO food additive series, no. 29. Toxicological evaluation of certain veterinary drug residues: 1991 [cited 26 Sep 2007]. Available at http://www.inchem.org/documents/jecfa/jecmono/ v29je01.htm.
78. Zaias, J. 2007. Personnel communication.
79. Zhao LZ, Chen J, Ee PLR, Chan E, Duan W, Guan YY, Hong YH, Chen X, Zhou S. 2006. Induction of propanolol metabolism by ginkgo biloba extract EGb 761 in rats. Curr Drug Metab 7:577-587.